Previous 10 | Next 10 |
2023-11-01 09:15:21 ET Summary Biocryst is a pharmaceutical company known for its oral therapy, ORLADEYO, used to prevent hereditary angioedema attacks. ORLADEYO has shown impressive revenue growth, earning $122m in 2021 and $250m in 2022. Biocryst's stock price has been decli...
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial evaluating BCX10013, a potential once-daily, oral Factor D inhibitor for the treatment of...
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will host an R&D Day at 1:00 p.m. ET on Friday, November 3, 2023, where the company plans to describe its drug discovery process and introduc...
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, November 2, 2023. BioCryst management will host a conference call and we...
2023-10-13 17:19:46 ET Gainers: Omeros Corporation ( NASDAQ: OMER ) +4% . BioCryst Pharmaceuticals ( BCRX ) +4% . Stitch Fix, Inc. ( SFIX ) +4% . Magnite ( MGNI ) +4% . Momentus ( MNTS ) +4% . Losers: Moderna. ( MRN...
RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positive recommendation for Pr ORLADEYO ® (berotrals...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-28 08:30:00 ET Growth stocks have lost momentum in August after a strong start to the year. The market is worried about the impact of a possible recession, high inflation, and high interest rates on the future earnings of companies. However, smart investors know that market downturn...
2023-08-15 12:49:49 ET More on Pharvaris Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development Pharvaris stock climbs 13% after FDA lifts hold on HAE drug candidate Pharvaris adds 58% on positive data from mid-stage hereditary angioedema trial P...
2023-08-14 09:31:04 ET Summary BioCryst's Q2 2023 earnings report showed a 25.9% YOY revenue rise, mainly from Orladeyo, with a net loss of $75.3M. Concerns arise due to declining liquidity, significant debt, and competition; however, Orladeyo shows promising growth potential. ...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...